Related Experiment Videos
Early versus late dexamethasone treatment in preterm infants at risk for chronic lung disease: a randomized pilot
U Merz1, T Peschgens, G Kusenbach
1Neonatal Intensive Care Unit, Children's Hospital, University of Technology, Aachen, Germany.
Insights
Early dexamethasone treatment in premature infants reduced ventilator and oxygen needs but showed no long-term lung function benefits. This study compared early versus late dexamethasone (Dex) for chronic lung disease (CLD) risk.
Area of Science:
- Neonatal Medicine
- Pediatric Pulmonology
- Pharmacology
Background:
- Chronic lung disease (CLD) is a significant concern in premature infants.
- Dexamethasone (Dex) is used to manage CLD, but optimal timing is debated.
Purpose of the Study:
- To compare the short- and long-term efficacy of early versus late dexamethasone treatment.
- To evaluate the impact of treatment timing on ventilator weaning, oxygen dependency, and lung function in preterm infants.
Main Methods:
- A controlled, prospective pilot study involving 30 ventilated premature infants (< or = 1250 g birth weight).
- Infants were randomized to receive dexamethasone (Dex) starting on day 7 (early) or day 14 (late).
- Treatment duration was 16 days, tapering from 0.5 to 0.1 mg/kg/day; lung function was assessed at 3 months via body plethysmography.
Main Results:
- Early Dex treatment significantly reduced time to ventilator weaning (14 vs. 24 days) and duration of supplemental oxygen (24 vs. 40 days).
- Oxygen dependency at 28 days of age and pulmonary function test results at 3 months showed no statistically significant differences between early and late treatment groups.
Conclusions:
- Early dexamethasone administration facilitated earlier extubation and reduced oxygen requirements in preterm infants.
- However, early treatment did not confer significant long-term advantages in oxygen dependency or pulmonary function at 3 months of age.
Unlabelled:
Abstract The purpose of this controlled, prospective pilot study was to compare the short-and long-term efficacy of early versus late treatment with dexamethasone (Dex) in preterm infants at risk for chronic lung disease (CLD). Thirty ventilated premature infants with a birth weight < or = 1250 g were randomized to receive Dex either from day 7 or from day 14. Dex was administered over 16 days tapering from 0.5 mg/kg per day to 0.1 mg/kg per day. The infants of the early treatment group could be weaned significantly earlier from the ventilator after 14 days (median; range 9-24) versus 24 days (median; range 8-44) in the late treatment group. The need for supplemental oxygen was shorter if Dex was started early - 24 days (median; range 10-57) versus 40 days (median; range 10-74). Oxygen dependency at 28 days of age was similar between the groups 6 out of 14 infants (42.9%) versus 10 out of 16 patients (62.5%). The long-term efficacy of the two Dex regimens on lung function was evaluated by body plethysmographic measurements made at the age of 3 months. Thoracic gas volume and airway resistance were measured and specific airway conductance calculated. No statistically significant differences between the groups were demonstrated.
Conclusion:
Early dexamethasone treatment led to earlier extubation in our study population, but was not associated with significant advantages regarding oxygen dependency at 28 days of life and pulmonary function test at 3 months of age.